Skip to main content
All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q4 report for BIOWOUND SOLUTIONS on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for BIOWOUND SOLUTIONS · Biologics Company

All filings by THE MCMANUS GROUP · Everything BIOWOUND SOLUTIONS has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Nevada

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)

 Bills named in this filing 3
  • H.R. 5768
    Skin Substitute Access and Payment Reform Act
  • S. 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • H.R. 6852
    Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem